https://doi.org/10.55788/f0a950d9
In a study in laboratory animals, which aimed to assess the role of the locus coeruleus in migraine-related pain processing, C57Bl/6J mice received either a stereotaxic injection with the CAV-PRS-hM3Dq-mCherry canine adenovirus or a control administered directly to the locus coeruleus [1]. “This virus contained a noradrenergic specific PRS promoter in order to drive DREADD [Designer Receptors Exclusively Activated by Designer Drugs] expression exclusively within these noradrenergic neurons,” said Dr Veronica Munday (King’s College London, UK). The DREADD used for the study was hM3Dq, a modified human muscarinic 3 receptor that does not respond to endogenous ligands, “but which can be activated by the designer ligand clozapine N-oxide.”
At the 60- and 90-minute timepoint after administration of clozapine N-oxide, mice in the control group had stable 50% mechanical activation thresholds, while mice who received the excitatory DREADD had significantly increased thresholds (P<0.05 at both timepoints). “This result suggests that activation of the locus coeruleus has a potential nociceptive effect,” said Dr Munday. The results were further assessed in a nitroglycerin model of induced cutaneous allodynia. Following nitroglycerin administration, there was a significant decrease in 50% mechanical activation thresholds, which reverts to baseline values after clozapine N-oxide administration.
“Overall, activation of the locus coeruleus can modulate nociceptive processing and is potentially nociceptive,” said Dr Munday. “This highlights that the locus coeruleus is a key region in migraine processing,” she continued, adding that the next steps involve assessing the role of the locus coeruleus in migraine-related sleep alteration and determining the specific pathways through which the locus coeruleus is involved in migraine and sleep.
- Munday V, et al. The brainstem locus coeruleus and migraine. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura Next Article
Early ESA use improves hematologic response duration in lower-risk MDS patients with anemia »
« Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura Next Article
Early ESA use improves hematologic response duration in lower-risk MDS patients with anemia »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
August 18, 2021
Occipital nerve stimulation in drug-resistant cluster headache
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
